Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity

Models, Molecular 0301 basic medicine Neurons/cytology/drug effects Estrogen Receptor alpha/agonists/biosynthesis Estrogen Receptor beta/agonists/biosynthesis Molecular Conformation Apoptosis Cell Proliferation/drug effects Structure-Activity Relationship 03 medical and health sciences Cell Line, Tumor Animals Estrogen Receptor beta Humans Cell Proliferation Neurons Estrogen Receptor alpha Dehydroepiandrosterone Apoptosis/*drug effects Neuroprotective Agents/adverse effects/*chemical synthesis/pharmacology Rats 3. Good health Neuroprotective Agents synthesis/pharmacology Dehydroepiandrosterone/adverse effects/*analogs & derivatives/*chemical
DOI: 10.1021/jm900468p Publication Date: 2009-11-05T06:43:08Z
ABSTRACT
DHEA analogues with modifications at positions C3 or C17 were synthesized and evaluated for neuroprotective activity against the neural-crest-derived PC12 cell model of serum deprivation-induced apoptosis. The most potent compounds were the spiro-epoxy derivatives 17beta-spiro[5-androstene-17,2'-oxiran]-3beta-ol (20), (20S)-3beta,21-dihydroxy-17beta,20-epoxy-5-pregnene (23), and (20R)-3beta,21-dihydroxy-17alpha,20-epoxy-5-pregnene (27) with IC(50) values of 0.19 +/- 0.01, 99.0 +/- 4.6, and 6.4 +/- 0.3 nM, respectively. Analogues 20, 23, and 27, up to the micromolar range of concentrations, were unable to activate estrogen receptor alpha and beta (ERalpha and ERbeta) or to interfere with ER-dependent gene expression significantly. In addition, they were unable to stimulate the growth of Ishikawa, MCF-7, and LNCaP cells. Our results suggest that the spiro-epoxyneurosteroid derivatives 20, 23, and 27 may prove to be lead molecules for the synthesis of novel neuroprotective agents.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (96)
CITATIONS (52)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....